Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Vivoryon Therapeutics reports promising Phase 2 results from its VIVA-MIND study, highlighting varoglutamstat’s significant improvement in kidney function, despite the study’s discontinuation due to unmet endpoints in Alzheimer’s disease. This supports the potential advancement of varoglutamstat in treating diabetic kidney disease, reinforcing previous findings from the VIVIAD study. The drug continues to show a favorable safety profile, bolstering its prospects in clinical development.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.
